/vt/ - Virtual Youtubers

>>22569280
I am a scientist, but not biomedical, but there's some quotes there that can answer your question:

"Rodríguez-Ubreva and Ballestar: We have identified several cellular pathways that are altered and could be targeted with existing drugs. More research expanding the number of patients will be needed to consider complementary or alternative therapeutic options."

In a nutshell, they have noticed some things that can be targeted with possible therapeutic drugs, but since the research they were doing was about specific patients (identical twins), what they saw could have been only specific to those people, which they point out in the next response:

"Rodríguez-Ubreva and Ballestar: Our study provides the first atlas of CVID. However, as indicated, this is a heterogeneous clinical entity, and it is critical to expand these studies by incorporating more patients and having different subtypes. This information could be useful to better characterize patients and give additional clues on which pathways are good candidates to explore novel therapeutic options. In this sense, close collaboration with clinical groups, expert in immunodeficiencies, is essential."

So, if they've made some kind of interesting discovery that can be exploited, we're talking about still years before they can identify what therapeutics will work broadly and generally and what ones are going to be patient specific. It seems they have noted some important differences between the two samples that give them an idea where they can start looking for fixes, but we're no where close to having anything that can help Mousey or any other CVID patient yet beyond the ones they've analyzed.